FOXO FOXO TECHNOLOGIES INC.
Debt Financing ·
FOXO Technologies signed agreements to acquire preferred stock carrying majority voting power in Ludwig Enterprises, Inc. and to buy certain Ludwig notes. The transactions have not closed.
FOXO subsidiary Vector BioSource, Inc. signed a definitive agreement to acquire four U.S. blood collection centers from Grifols Bio Supplies, Inc. The company expects the deal to close in the third or fourth quarter of 2026.
In a letter to shareholders, CEO Seamus Lagan reported first quarter 2026 net revenues of about $5.1 million, completed a 1:3,000 reverse stock split, and said FOXO is considering an uplisting to a recognized exchange before the end of 2026.
The reverse split of FOXO's Class A common stock took effect at 4:01 p.m. ET on June 30, 2026. Shares trade on a split-adjusted basis under the temporary symbol FOXOD until the symbol reverts to FOXO on or about July 20, 2026.
FOXO Technologies and LongevityFP Technologies, LLC signed an exclusive license on May 28, 2026. LongevityFP will pay a royalty of three percent of its net revenues, capped at $1.3 million.
FOXO settled amounts owed to J.H. Darbie & Co., Inc. with preferred stock and $175,000 in installments. Its majority holder approved a reverse split at a ratio of 1:1,000 to 1:10,000.
Two institutional holders swapped Series A preferred stock for non-convertible notes of $5,307,096.94 and $2,467,988.34, due May 12, 2027.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $16.4 million | $4.1 million |
| Research and development | $182,498 | $312,267 |
| Net income (loss) | -$12.4 million | -$12.4 million |
| Cash from operations | -$3.9 million | -$2.8 million |
| Cash and equivalents | $207,453 | $68,268 |
Our latest story on this, dated Jul 6, 2026: "FOXO CEO gives mid-year 2026 update and says uplisting is under consideration". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 12, 2026: "FOXO exchanges Series A preferred for senior unsecured notes". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 29, 2026: "FOXO to buy Ludwig Enterprises preferred stock with majority voting power". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 22, 2026: "FOXO settles J.H. Darbie fees and seeks a reverse stock split". The story links the filing or release it is based on. Read the story.
FOXO TECHNOLOGIES INC. trades under the ticker FOXO on OTC.
FOXO TECHNOLOGIES INC. is listed on OTC.
Our directory records FOXO TECHNOLOGIES INC. under United States.
aibio.space lists FOXO TECHNOLOGIES INC. among 2,820 public biotech companies and publishes its news here as stories appear.
$16.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
FOXO TECHNOLOGIES INC. reported a net loss of $12.4 million for the fiscal year ended Dec 31, 2025, and used $3.9 million of cash in operations, per its annual report to the SEC.
$182,498 in the fiscal year ended Dec 31, 2025, per its annual report.
$58,409 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on FOXO TECHNOLOGIES INC., dated Oct 29, 2026: "FOXO to buy Ludwig Enterprises preferred stock with majority voting power". FOXO Technologies signed agreements to acquire preferred stock carrying majority voting power in Ludwig Enterprises, Inc. and to buy certain Ludwig notes. The transactions have not closed. Source.
Our latest financing story, dated May 22, 2026: "FOXO settles J.H. Darbie fees and seeks a reverse stock split". FOXO settled amounts owed to J.H. Darbie & Co., Inc. with preferred stock and $175,000 in installments. Its majority holder approved a reverse split at a ratio of 1:1,000 to 1:10,000. Source.
From our story of May 28, 2026: The release does not give a current cash balance or a cash runway estimate. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio